etiprednol dicloacetate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00035503)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[C@@]1(OC(=O)C(Cl)Cl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C- Mol. weight
- 485.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107614 ↗
Also known as
- bnp166
- bnp166
- bnp166
- bnp166
- bnp166
- bnp166
- bnp-166
- bnp-166
- bnp-166
- ethyl-17alpha-dichloroacetoxy-11beta-hydroxyandrosta-1,4-diene-3-one-17beta-carboxylate
- etiprednol dichloroacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
- etiprednol dicloacetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00035503 | Phase 2 | Jan 1, 2002 | Teva |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1